

9th Annual Brain Metastases Research and Emerging Therapy Conference

**October 4-5, 2019
Marseille, France**

PROGRAM CHAIRS

Manmeet Ahluwalia (US)
Frédéric Dhermain (FR)
Emilie Le Rhun (FR)
Philippe Métellus (FR)
Michael Weller (CH)
Manfred Westphal (DE)



METIS

Brain Metastasis

Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC).

Primary Endpoint: Time to intracranial progression

Diagnosis

Screening

Randomization

SRS

Device
start

Main Inclusion Criteria *

- New diagnosis of brain metastases from NSCLC
- Karnofsky performance status (KPS) ≥ 70
- Life expectancy of ≥ 3 months
- Must have 1 – 10 brain lesions per screening MRI
- Cumulative volume of all tumors ≤ 15 cc

Main Exclusion Criteria *

- Leptomeningeal metastases
- Somatic tumor mutations: ALK, EGFR, ROS-1, B-RAF
- Recurrent brain metastases
- Prior WBRT
- Implantable electronic medical devices in the brain

*This is a summary of main eligibility criteria as listed on [clinicaltrials.gov \(NCT 02831959\)](https://clinicaltrials.gov/NCT02831959).

Refer to protocol for complete listing of Inclusion/Exclusion Criteria

Would you like to know more?

If you are interested in participating in our clinical research study or have questions regarding METIS or TTFields, please visit novocuretrial.com or contact jommer@novocure.com



novocure®

patientforward

Tumor Treating Fields (TTFields) are not approved in the United States or CE marked in Europe for the treatment of brain metastasis. The safety and effectiveness of TTFields for this use has not been established.

©2019 Novocure. Novocure is a registered trademark of Novocure. All rights reserved.



Welcome Letter

We are pleased to welcome you to Marseille for the 9th Annual Brain Metastases Research and Emerging Therapy Conference. Last year's successful edition encouraged us to once again organize this conference.

This year the meeting will be held under the auspices of EORTC, EANS, EANO, the French neuro-oncology group (ANOCEF) and the French society of neuro-surgery who are all partners of this event.


This initiative brings the multidisciplinary approach needed to develop Brain Metastases projects across several tumor types and disciplines such as breast cancer, lung cancer, melanoma, imaging, radiation oncology, pathology and molecular. It is expected that this cross-sectional meeting will stimulate innovative and insightful research in a collaborative environment and improve the standard of care and methodology of clinical research.

For this 9th edition, a special session will be dedicated to challenges in precision medicine and potential of liquid biopsies in CNS Metastases. Highlighted topics will also cover the increasing place of combined treatment in the era of targeted therapies and controversies in therapeutic management of BM.

One of the objectives of this edition will be to describe the clinical problem, identify the critical points of therapeutic failure and summarize the current state of knowledge of the genetics and biology of Brain Metastases. The overarching goal of the meeting is to generate a set of research priorities that would stimulate integrated scientific and clinical investigation directed at understanding basic processes of Brain Metastases and translating such insights to clinical care.

The organizing committee hopes that this meeting will provide an exceptional opportunity for you to share your collective expertise ranging from basic science to new treatments in order to facilitate ongoing studies and lay the foundation for future collaborative projects.

PROGRAM CHAIRS:
MANMEET AHLUWALIA, F. DHERMAIN, EMILIE LE RHUN,
PHILIPPE MÉTELLUS, MICHAEL WELLER & MANFRED WESTPHAL



Scientific program

Friday, October 4th

08.30 Welcome coffee

08.45 Welcome address, [Philippe Métellus \(FR\)](#)

09.00 Preclinical research in brain metastases

Chairs: [Andreas Von Deimling \(DE\)](#) & [David Reardon \(USA\)](#)

09.00 Anti-metastasis strategies targeting the microenvironment in mice and human, [Manuel Valiente \(SP\)](#)

09.30 Preclinical models of breast cancer brain metastases: translational implications, [Brunilde Gril \(USA\)](#)

10.00 Challenges in clinical practice

Chairs: [Dieta Brandsma \(NL\)](#) & [Manfred Westphal \(DE\)](#)

10.00 Steroids in neuro-oncology, [Manfred Westphal \(DE\)](#)

10.20 VTE in brain metastases patients, [Christine Marosi \(AU\)](#)

10.40 Seizures, brain metastases and anticonvulsants, [Martin van den Bent \(NL\)](#)

11.00 Coffee break and visit of the exhibition

11.20 Controversial treatments for CNS Metastases

Chairs: [Linda Dirven \(NL\)](#) & [Norbert Galldiks \(DE\)](#)

11.20 SRS should be a first-line treatment

Pro (5 min): [Frédéric Dhermain \(FR\)](#)

Cons (5 min): [Giuseppe Minniti \(IT\)](#)

Discussion (10 min)

11.40 Intra-CSF therapy is standard of care

Pro (5 min): [Michael Weller \(CH\)](#)

Cons (5 min): [Dieta Brandsma \(NL\)](#)

Discussion (10 min)

12.00 Tumor-treating fields

Pro (5 min): [Michael Weller \(CH\)](#)

Cons (5 min): [Martin van den Bent \(NL\)](#)

Discussion (10 min)

12.20 Keynote lecture

Chair: [Emilie Le Rhun \(FR\)](#)

12.20 Challenges and pitfalls in designing clinical trials in the CNS metastases field, [Thierry Gorlia \(BE\)](#)

12.50 Lunch

14.00 Controversies in Radiation Oncology

Chairs: Frédéric Dhermain (FR) & David Reardon (USA)

- 14.00 Prophylactic cranial irradiation
Pro (5 min): [Matthias Guckenberger \(CH\)](#)
Cons (5 min): [Linda Dirven \(NL\)](#)
Discussion (10 min)
- 14.20 Hippocampal sparing
Pro (5 min): [Giuseppe Minniti \(IT\)](#)
Cons (5 min): [Linda Dirven \(NL\)](#)
Discussion (10 min)
- 14.40 Combined immunotherapy and radiation therapy
Pro (5 min): [Frédéric Dhermain \(FR\)](#)
Cons (5 min): [Christine Marosi \(AU\)](#)
Discussion (10 min)

15.00 Interactive case reports (Electronic voting system)

Chairs: Philippe Métellus (FR) & Michael Weller (CH)

- 15.00 Case 1 - [Axel de Bernardi \(FR\)](#)
15.20 Case 2 - [Aurélien Maureille \(FR\)](#)

15.45 Coffee break and visit of the exhibition

16.15 Keynote lecture

Chair: Michael Weller (CH)

- 16.15 Immuno-oncology approaches to brain metastases,
[David Reardon \(USA\)](#)
- 17.00 Activities of EORTC BTG CNS Metastases Committee, [Emilie Le Rhun \(FR\)](#)
- 17.15 Poster session with the Scientific Committee


20.00 Gala dinner

Rowing Club

34 Boulevard Charles Livon, 13007 Marseille
www.restaurantrowingclub.com



Accreditation statement.
9 European CME credits (ECMEC) by the European Accreditation Council
for Continuing Medical Education (EACCME).



Scientific program

Saturday, October 5th

08.00 Welcome coffee

08.30 Selected oral presentations

Chairs: Frédéric Dhermain (FR) & Agnès Tallet (FR)

- 08.30 Preclinical antitumor activity of a new HER2 inhibitor on HER2-positive breast cancer and brain metastasis, [Camille Faure \(FR\)](#)
- 08.40 Identifying molecular drivers and developing in vitro and in vivo models in breast cancer leptomeningeal metastasis (BCLM), [Amanda Fitzpatrick \(UK\)](#)
- 08.50 Transcellular disruption of human blood-brain barrier endothelium by a subset of melanoma cells that remain in suspension, [Akshata Anchan \(NZ\)](#)
- 09.00 Patient-derived organoids and xenografts from resected brain metastases as a platform to optimize personalized drug treatment selection for brain metastases, [Sofia Merajver \(USA\)](#)
- 09.10 Characterization of genomic alterations of brain metastases in advanced non-small cell lung cancer: retrospective cohort, [Maxime Souquet-Bressand \(FR\)](#)
- 09.20 Venous thromboembolic events in patients with brain metastases: the PICOS score, [Fabian Wolpert \(CH\)](#)
- 09.30 Leucencephalopathy after prophylactic whole brain irradiation with or without hippocampal sparing: a long-term MRI analysis, [Michael Mayinger \(CH\)](#)
- 09.40 Subtype switching in breast cancer brain metastases: a multicenter analysis, [Alexander Hulsbergen \(USA\)](#)
- 09.50 Radiation-induced brain edema alone and in combination with T-DM1 in Her2+ brain metastases, [Maria Contreras-Zarate \(USA\)](#)
- 10.00 Whole brain radiotherapy (WBRT) as a palliative treatment for multiple brain metastases in Metastatic Melanoma, [Siobhan Morrison \(UK\)](#)

10.10 Coffee break and visit of the exhibition

10.30 Highlights 2018-2019

**Chairs: Andreas Von Deimling (DE)
& Martin J. Van den Bent (NL)**

- 10.30 Liquid biopsy, [Danijela Koppers-Lalic \(NL\)](#)
- 10.50 Methylation based diagnosis of tumors in the brain, [Andreas Von Deimling \(DE\)](#)
- 11.10 Molecular imaging, [Norbert Galldiks \(DE\)](#)
- 11.30 Neurosurgery, [Philippe Métellus \(FR\)](#)
- 11.50 What's hot in melanoma CNS metastasis? [Dieta Brandsma \(NL\)](#)
- 12.10 What's hot in breast cancer CNS metastasis? [Emilie Le Rhun \(FR\)](#)
- 12.30 What's hot in lung cancer CNS metastasis? [Matthias Guckenberger \(CH\)](#)

12.45 Awards – Best communication and poster – Conclusions

13.00 Lunch



Accreditation statement.

9 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Partners of the Conference

Major Sponsors



Sponsors



abbvie



KYOWA KIRIN

stryker®

Organization com&co

Com&Co - Etienne Jarry
15, Bd Grawitz - 13016 Marseille, France
Tel.: +33 (0)4 91 09 70 53 - Fax: +33 (0)4 96 15 33 08
Email: ejarry@comnco.com